Your browser doesn't support javascript.
loading
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Grivas, Petros; Mortazavi, Amir; Picus, Joel; Hahn, Noah M; Milowsky, Matthew I; Hart, Lowell L; Alva, Ajjai; Bellmunt, Joaquim; Pal, Sumanta K; Bambury, Richard M; O'Donnell, Peter H; Gupta, Sumati; Guancial, Elizabeth A; Sonpavde, Guru P; Faltaos, Demiana; Potvin, Diane; Christensen, James G; Chao, Richard C; Rosenberg, Jonathan E.
Afiliación
  • Grivas P; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Mortazavi A; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Picus J; Division of Oncology, Department of Medicine, Washington University in St. Louis, St Louis, Missouri.
  • Hahn NM; Departments of Oncology and Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Milowsky MI; Department of Medicine, Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
  • Hart LL; Florida Cancer Specialists, Fort Myers, Florida.
  • Alva A; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
  • Bellmunt J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Pal SK; Department of Medical Oncology, City of Hope, Duarte, California.
  • Bambury RM; Department of Medical Oncology, Cork University Hospital, Cork, Ireland.
  • O'Donnell PH; Department of Medicine, University of Chicago, Chicago, Illinois.
  • Gupta S; Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Guancial EA; Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, New York.
  • Sonpavde GP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Faltaos D; Clinical Pharmacology, Mirati Therapeutics Inc, San Diego, California.
  • Potvin D; Biostatistics and Data Management, Mirati Therapeutics Inc, San Diego, California.
  • Christensen JG; Research, Mirati Therapeutics Inc, San Diego, California.
  • Chao RC; Clinical Development, Mirati Therapeutics Inc, San Diego, California.
  • Rosenberg JE; Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
Cancer ; 125(4): 533-540, 2019 02 15.
Article en En | MEDLINE | ID: mdl-30570744
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirimidinas / Benzamidas / Carcinoma de Células Transicionales / Regulación Neoplásica de la Expresión Génica / Neoplasias Urológicas / Proteína de Unión a CREB / Proteína p300 Asociada a E1A / Mutación Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirimidinas / Benzamidas / Carcinoma de Células Transicionales / Regulación Neoplásica de la Expresión Génica / Neoplasias Urológicas / Proteína de Unión a CREB / Proteína p300 Asociada a E1A / Mutación Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2019 Tipo del documento: Article